Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Fudan University50 enrolled

Overview

To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Breast Cancer

Interventions

PalbociclibDRUG

Palbociclib 125mg/d

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Female patients aged 18-70 years. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. HR+ was defined as estrogen receptor- or progesterone receptor-positive status by immunohistochemistry. 4. HER2 status was determined by immunohistochemistry or fluorescence in situ hybridization. 5. Palbociclib treatment of metastatic breast cancer for at least one cycle. 6. Available medical history. Exclusion Criteria: 1.Incomplete medical history.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, China

Outcomes

Primary Outcomes

PFS

Time frame: Through study completion, an expected average of 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.